The facts about sexual (dys)function in schizophrenia: An overview of clinically relevant findings

Schizophrenia Bulletin

Volumn 41, Issue 3, 2015, Pages 674-686

  De Boer, Marrit K ^a   Castelein, Stynke ^a,b   Wiersma, Durk ^a   Schoevers, Robert A ^a   Knegtering, Henderikus ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Lentis   (Netherlands)

Author keywords

Antipsychotic; Dopamine; Negative symptoms; Prolactin; Schizophrenia; Sexual dysfunction

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; PHOSPHODIESTERASE V INHIBITOR;

ARTICLE; DRUG INDUCED DISEASE; EJACULATION; ERECTILE DYSFUNCTION; GALACTORRHEA; GYNECOMASTIA; HUMAN; MENSTRUATION DISORDER; ORGASM; PATIENT COUNSELING; PRACTICE GUIDELINE; PREVALENCE; PRIAPISM; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOPHYSIOLOGY; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SEXUAL DESIRE; SEXUAL DYSFUNCTION; SEXUAL EDUCATION; SEXUALITY; SOCIAL INTERACTION; SOCIAL PSYCHOLOGY; VAGINAL LUBRICATION; ADULT; CHEMICALLY INDUCED; COMPLICATION; FEMALE; MALE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; SCHIZOPHRENIA; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 84942518152     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv001     Document Type: Article

References (125)

1. Aizenberg D, Zemishlany Z, Dorfman-Etrog P, Weizman A. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry. 1995;56:137-141.
2. Marques TR, Smith S, Bonaccorso S, et al. Sexual dysfunction in people with prodromal or first-episode psychosis. Br J Psychiatry. 2012;201:131-136.
3. Fujii A, Yasui-Furukori N, Sugawara N, et al. Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:288-293.
4. Malik P, Kemmler G, Hummer M, et al. Sexual dysfunction in first-episode schizophrenia patients: Results from european first episode schizophrenia trial. J Clin Psychopharmacol. 2011;31:274-280.
5. Knegtering H, van den Bosch R, Castelein S, Bruggeman R, Sytema S, van Os J. Are sexual side effects of prolactin- raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology. 2008;33:711-717.
6. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol. 2008;23:201-209.
7. Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 2011;26:130-140.
8. Olfson M, Uttaro T, Carson WH, Tafesse E. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry. 2005;66:331-338.
9. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21:911-936.
10. Finn SE, Bailey JM, Schultz RT, Faber R. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med. 1990;20:843-848.
11. Jacobs P, Bobek SC. Sexual needs of the schizophrenic client. Perspect Psychiatr Care. 1991;27:15-20.
12. Norman JP. Evidence and clinical significance of homosexuality in 100 unanalyzed cases of dementia praecox. J Nerv Ment Dis. 1948;107:484-489.
13. Arieti S. New views on the psychodynamics of schizophrenia. Am J Psychiatry. 1967;124:453-458.
14. Akhtar S, Thomson JA Jr. Schizophrenia and sexuality: a review and a report of twelve unusual cases-Part II. J Clin Psychiatry. 1980;41:166-174.
15. Connolly FH, Gittleson NL. The relationship between delusions of sexual change and olfactory and gustatory hallucinations in schizophrenia. Br J Psychiatry. 1971;119:443-444.
16. Skopec HM, Rosenberg SD, Tucker GJ. Sexual behavior in schizophrenia. Med Aspects Hum Sex. 1976;10:32.
17. Perry BL, Wright ER. The sexual partnerships of people with serious mental illness. J Sex Res. 2006;43:174-181.
18. Verhulst J, Schneidman B. Schizophrenia and sexual functioning. Hosp Community Psychiatry. 1981;32:259-262.
19. Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry. 2010;22:417-428.
20. McGlashan TH, Bardenstein KK. Gender differences in affective, schizoaffective, and schizophrenic disorders. Schizophr Bull. 1990;16:319-329.
21. McEvoy JP, Hatcher A, Appelbaum PS, Abernethy V. Chronic schizophrenic women's attitudes toward sex, pregnancy, birth control, and childrearing. Hosp Community Psychiatry. 1983;34:536-539.
22. Hilger T, Propping P, Haverkamp F. Is there an increase of reproductive rates in schizophrenics? III. An investigation in Nordbaden (SW Germany): results and discussion. Arch Psychiatr Nervenkr. 1983;233:177-186.
23. Wignall CM, Meredith CE. Illegitimate pregnancies in state institutions. Arch Gen Psychiatry. 1968;18:580-583.
24. Appleby L, Desai PN, Luchins DJ, Gibbons RD, Hedeker DR. Length of stay and recidivism in schizophrenia: a study of public psychiatric hospital patients. Am J Psychiatry. 1993;150:72-76.
25. Odegård O. Fertility of psychiatric first admissions in Norway 1936-1975. Acta Psychiatr Scand. 1980;62:212-220.
26. Nicholson J, Geller JL, Fisher WH. "Sylvia Frumkin" has a baby: a case study for policymakers. Psychiatr Serv. 1996;47:497-501.
27. Raboch J. The sexual development and life of female schizophrenic patients. Arch Sex Behav. 1984;13:341-349.
28. Lyketsos GC, Sakka P, Maïlis A. The sexual adjustment of chronic schizophrenics: a preliminary study. Br J Psychiatry. 1983;143:376-382.
29. Strauss B, Gross J. [Psychotropic drug-induced changes in sexuality-frequency and relevance in psychiatric practice]. Psychiatr Prax. 1984;11:49-55.
30. Pinderhughes CA, Grace EB, Reyna LJ. Psychiatric disorders and sexual functioning. Am J Psychiatry. 1972;128:1276-1283.
31. Buddeberg C, Furrer H, Limacher B. Sexual problems in schizophrenic patients treated by ambulatory care. Psychiatr Prax. 1988;15:187-191.
32. Lukoff D, Gioia-Hasick D, Sullivan G, Golden JS, Nuechterlein KH. Sex education and rehabilitation with schizophrenic male outpatients. Schizophr Bull. 1986;12:669-677.
33. McCann E. The expression of sexuality in people with psychosis: breaking the taboos. J Adv Nurs. 2000;32:132-138.
34. Kelly DL, Conley RR. Evaluating sexual function in patients with treatment-resistant schizophrenia. Schizophr Res. 2003;63:195-196.
35. Dossenbach M, Hodge A, Anders M, et al. Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. Int J Neuropsychopharmacol. 2005;8:195-201.
36. Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003;28(suppl 2):109-123.
37. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
38. Sullivan G, Lukoff D. Sexual side effects of antipsychotic medication: evaluation and interventions. Hosp Community Psychiatry. 1990;41:1238-1241.
39. Dossenbach M, Hodge A, Anders M, et al. Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. Int J Neuropsychopharmacol. 2005;8:195-201.
40. Mitchell KR, Mercer CH, Ploubidis GB, et al. Sexual function in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Lancet. 2013;382:1817-1829.
41. Knegtering R, Castelein S, Bous H, et al. A randomized openlabel study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol. 2004;24:56-61.
42. Knegtering H, Boks M, Blijd C, Castelein S, van den Bosch RJ, Wiersma D. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther. 2006;32:315-326.
43. de Boer MK, Wiersma D, Bous J, et al. A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study). J Clin Psychopharmacol. 2011;31:523-525.
44. Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry. 2000;57:1012-1030.
45. Compton MT, Miller AH. Priapism associated with conventional and atypical antipsychotic medications: a review. J Clin Psychiatry. 2001;62:362-366.
46. Sood S, James W, Bailon MJ. Priapism associated with atypical antipsychotic medications: a review. Int Clin Psychopharmacol. 2008;23:9-17.
47. Patel AG, Mukherji K, Lee A. Priapism associated with psychotropic drugs. Br J Hosp Med. 1996;55:315-319.
48. Bucur M, Mahmood T. Olanzapine-induced clitoral priapism. J Clin Psychopharmacol. 2004;24:572-573.
49. Munarriz R, Kim SW, Kim NN, Traish A, Goldstein I. A review of the physiology and pharmacology of peripheral (vaginal and clitoral) female genital arousal in the animal model. J Urol. 2003;170:S40-4; discussion S44.
50. van Netten JJ, Georgiadis JR, Nieuwenburg A, Kortekaas R. 8-13 Hz fluctuations in rectal pressure are an objective marker of clitorally-induced orgasm in women. Arch Sex Behav. 2008;37:279-285.
51. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis. 1982;170:463-467.
52. Shader RI, Elkins R. The effects of antianxiety and antipsychotic drugs and sexual behavior. Mod Probl Pharmacopsychiatry. 1980;15:91-110.
53. Girgis SM, Etriby A, el-Hefnawy H, Kahil S. Aspermia: a survey of 49 cases. Fertil Steril. 1968;19:580-588.
54. Kotin J, Wilbert DE, Verburg D, Soldinger SM. Thioridazine and sexual dysfunction. Am J Psychiatry. 1976;133:82-85.
55. van Bruggen M, van Amelsvoort T, Wouters L, Dingemans P, de Haan L, Linszen D. Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroendocrinology. 2009;34:989-995.
56. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl). 1996;124:168-175.
57. Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry. 1994;55:406-413.
58. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001;76:1521-1531.
59. Keitner GI, Selub S. Spontaneous ejaculations and neuroleptics. J Clin Psychopharmacol. 1983;3:34-36.
60. Ouwehand AJ, Mollema-Schelwald BM, Knegtering H. [The relationship between antipsychotic-induced hyperprolactinemia and menstrual disorders in women with schizophrenia; a systematic review]. Tijdschr Psychiatr. 2012;54:861-868.
61. Aizenberg D, Modai I, Landa A, Gil-Ad I, Weizman A. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J Clin Psychiatry. 2001;62:541-544.
62. Berger SH. Trifluoperazine and haloperidol: sources of ejaculatory pain? Am J Psychiatry. 1979;136:350.
63. Donnellan P, Breathnach O, Crown JP. Odynorgasmia. Scand J Urol Nephrol. 2001;35:158.
64. Giuliano F, Allard J. Dopamine and sexual function. Int J Impot Res. 2001;13(suppl 3):S18-S28.
65. Bressan RA, Crippa JA. The role of dopamine in reward and pleasure behaviour-review of data from preclinical research. Acta Psychiatr Scand Suppl. 2005;427:14-21.
66. Fitzgerald P, Dinan TG. Prolactin and dopamine: What is the connection? A review article. J Psychopharmacol. 2008;22(2 suppl):12-19.
67. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res. 1999;35 (suppl):S75-S86.
68. Hummer M, Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin. 2004;20:189-197.
69. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychoticinduced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164:1404-1410.
70. Rettenbacher MA, Hofer A, Ebenbichler C, et al. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J Clin Psychopharmacol. 2010;30:711-715.
71. Westheide J, Cohen S, Bender S, et al. Sexual dysfunction in psychiatric inpatients the role of antipsychotic medication. Pharmacopsychiatry. 2007;40:140-145.
72. Nakonezny PA, Byerly MJ, Rush AJ. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther. 2007;33:203-216.
73. Howes OD, Wheeler MJ, Pilowsky LS, Landau S, Murray RM, Smith S. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2007;68:361-367.
74. Knegtering H, Bruggeman R, Castelein S, Wiersma D. [Antipsychotics and sexual functioning in persons with psychoses]. Tijdschr Psychiatr. 2007;49:733-742.
75. Leysen JE, Gommeren W. The dissociation rate of unlabelled dopamine antagonists and agonists from the dopamine-D2 receptor, application of an original filter method. J Recept Res. 1984;4:817-845.
76. Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK. Role of serotonin and dopamine receptor binding in antipsychotic efficacy. Prog Brain Res. 2008;172:155-175.
77. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(suppl 2):S12-S21.
78. Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol. 2009;29:157-164.
79. Gelenberg AJ, McGahuey C, Laukes C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry. 2000;61:356-360.
80. Thompson JW Jr, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry. 1990;51:430-433.
81. Sanbe A, Tanaka Y, Fujiwara Y, et al. Alpha1-adrenoceptors are required for normal male sexual function. Br J Pharmacol. 2007;152:332-340.
82. Smith ER, Lee RL, Schnur SL, Davidson JM. Alpha 2-adrenoceptor antagonists and male sexual behavior: II. Erectile and ejaculatory reflexes. Physiol Behav. 1987;41:15-19.
83. Tallentire D, McRae G, Spedding M, Clark R, Vickery B. Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS- 15385-197). Br J Pharmacol. 1996;118:63-72.
84. Floody OR. Cholinergic control of male mating behavior in hamsters: effects of systemic agonist or antagonist treatment. Pharmacol Biochem Behav. 2011;100:289-298.
85. Canevelli M, Talarico G, Tosto G, Troili F, Lenzi GL, Bruno G. Rivastigmine in the treatment of hypersexuality in Alzheimer disease. Alzheimer Dis Assoc Disord. 2013;27:287-288.
86. White JM, Rumbold GR. Behavioural effects of histamine and its antagonists: a review. Psychopharmacology (Berl). 1988;95:1-14.
87. Uckert S, Wilken M, Stief C, Trottmann M, Kuczyk M, Becker A. Is there a significance of histamine in the control of the human male sexual response? Andrologia. 2012;44(suppl 1):538-542.
88. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124:57-73.
89. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29-39.
90. Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther. 2002;302:1129-1134.
91. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry. 2005;162:1010-1012.
92. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry. 2005;66:761-767.
93. Nestoros JN, Lehmann HE, Ban TA. Sexual behavior of the male schizophrenic: the impact of illness and medications. Arch Sex Behav. 1981;10:421-442.
94. Östman M, Björkman AC. Schizophrenia and relationships: the effect of mental illness on sexuality. Clin Schizophr Relat Psychoses. 2013;7:20-24.
95. Ostman M. Low satisfaction with sex life among people with severe mental illness living in a community. Psychiatry Res. 2014;216:340-345.
96. Miller LJ, Finnerty M. Sexuality, pregnancy, and childrearing among women with schizophrenia-spectrum disorders. Psychiatr Serv. 1996;47:502-506.
97. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64:2291-2314.
98. Nunes LV, Moreira HC, Razzouk D, Nunes SO, Mari Jde J. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex Marital Ther. 2012;38:281-301.
99. Gopalakrishnan R, Jacob KS, Kuruvilla A, Vasantharaj B, John JK. Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebocontrolled, flexible-dose, two-way crossover trial. Am J Psychiatry. 2006;163:494-499.
100. Nunes LV, Lacaz FS, Bressan RA, Nunes SO, Mari Jde J. Adjunctive treatment with lodenafil carbonate for erectile dysfunction in outpatients with schizophrenia and spectrum: a randomized, double-blind, crossover, placebo-controlled trial. J Sex Med. 2013;10:1136-1145.
101. de Boer MK, Oolders JM, van den Heuvel ER, Wiersma D, Schoevers RA, Knegtering H. Efficacy of tadalafil on erectile dysfunction in male patients using antipsychotics: A double- blind, placebo-controlled, crossover pilot study. J Clin Psychopharmacol. 2014;34(3):380-382.
102. Kodesh A, Weizman A, Aizenberg D, Hermesh H, Gelkopf M, Zemishlany Z. Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study. Clin Neuropharmacol. 2003;26:193-195.
103. Lee HS, Song DH, Kim JH, Lee YM, Han ES, Yoo KJ. Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 1995;10:67-72.
104. Byerly MJ, Nakonezny PA, Rush AJ. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial. Psychiatry Res. 2008;159:115-120.
105. Mir A, Shivakumar K, Williamson RJ, McAllister V, O'Keane V, Aitchison KJ. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol. 2008;22:244-253.
106. Chen JX, Su YA, Wang SL, et al. Aripiprazole treatment of risperidone-induced hyperprolactinemia. J Clin Psychiatry. 2009;70:1058-1059.
107. Yasui-Furukori N, Furukori H, Sugawara N, Fujii A, Kaneko S. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol. 2010;30:596-599.
108. Mitsonis CI, Mitropoulos PA, Dimopoulos NP, et al. Vardenafil in the treatment of erectile dysfunction in outpatients with chronic schizophrenia: a flexible-dose, open-label study. J Clin Psychiatry. 2008;69:206-212.
109. Yuan HN, Wang CY, Sze CW, et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol. 2008;28:264-370.
110. Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry. 2004;65:187-190.
111. Correa N, Opler LA, Kay SR, Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol. 1987;7:91-95.
112. Valevski A, Modai I, Zbarski E, Zemishlany Z, Weizman A. Effect of amantadine on sexual dysfunction in neuroleptictreated male schizophrenic patients. Clin Neuropharmacol. 1998;21:355-357.
113. Yamada K, Kanba S, Yagi G, Asai M. Effectiveness of herbal medicine (shakuyaku-kanzo-to) for neuroleptic-induced hyperprolactinemia. J Clin Psychopharmacol. 1997;17:234-235.
114. Aizenberg D, Shiloh R, Zemishlany Z, Weizman A. Low-dose imipramine for thioridazine-induced male orgasmic disorder. J Sex Marital Ther. 1996;22:225-229.
115. Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:714-717.
116. Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1978-1981.
117. Byerly MJ, Marcus RN, Tran QV, Eudicone JM, Whitehead R, Baker RA. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009;107:218-222.
118. Montejo AL, Rico-Villademoros F; Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study. J Clin Psychopharmacol. 2008;28:568-570.
119. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:595-600.
120. Kaneda Y, Kawamura I, Fujii A, Ohmori T. Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia. Neuro Endocrinol Lett. 2004;25:135-140.
121. Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology. 2006;31:577-588.
122. Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry. 2002;63:408-413.
123. Lin CY, Wu PL, Pariante CM, Su KP. A crossover study of prolactin changes associated with risperidone and olanzapine. J Clin Psychiatry. 2006;67:1470.
124. Nakajima M, Terao T, Iwata N, Nakamura J. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia. Pharmacopsychiatry. 2005;38:17-19.
125. Byerly MJ, Lescouflair E, Weber MT, et al. An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. J Sex Marital Ther. 2004;30:325-332.